Objectives: To develop a mapping algorithm for estimating EuroQol five-dimensional (EQ-5D) questionnaire values from the prostate cancer-specific health-related quality-of-life (HRQOL) instrument Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument. Methods: The EQ-5D questionnaire and FACT-P instrument data were collected for a subset of patients with metastatic castrationresistant prostate cancer in a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. We compared three statistical techniques to estimate patients' EQ-5D questionnaire index scores determined by using the UK tariff: 1) generalized estimating equations, 2) two-part model combining logistic regression and generalized estimating equation, and 3) separate mapping algorithms for patients with poor health defined as a FACT-P score of 76 or less (group-specific model). Four different sets of explanatory variables were compared. The models were cross-validated by using a 10-fold in-sample crossvalidation. Results: Values for both instruments were available for 236 patients with metastatic castration-resistant prostate cancer. The group-specific model including the FACT-P subscale scores and baseline variables had the best predictive performance with R 2 0.718, root mean square error 0.162, and mean absolute error 0.117. The two-part model and the generalized estimating equation model including the FACT-P subdomain scores and baseline variables also had good predictive performance. Conclusions: The developed algorithms for mapping the FACT-P instrument to the EQ-5D questionnaire enable the estimation of preference-based health-related quality-of-life scores for use in cost-effectiveness analyses when directly elicited EQ-5D questionnaire data are missing.
Introduction
Data on health-related quality of life (HRQOL) measures, such as the Functional Assessment of Cancer Therapy-Prostate (FACT-P), are routinely collected in oncology studies. These HRQOL tools do not provide preference-based scores, which are crucial for developing cost-utility models used to inform health-related resource allocation. The National Institute for Health and Care Excellence (NICE) in England and Wales states that its preferred measure of outcome for economic evaluation is the quality-adjusted lifeyear, and the EuroQol five-dimensional (EQ-5D) questionnaire is the preferred measure of health-related utility required to incorporate the quality-of-life element [1] . In the absence of preference-based scores, such as those derived from the EQ-5D questionnaire, a statistical model can be estimated that "maps" the HRQOL measures to utility values.
Mapping functions have been developed for multiple HRQOL instruments in different areas, such as cancer [2] [3] [4] [5] , HIV [6] , cardiology [7] , arthritis [8] , and ophthalmology [9] . There are currently no "standard" models for mapping, and different statistical techniques have been used to take account of the nature of EQ-5D questionnaire utility data, that is, negatively skewed and with an upper bound at value 1 representing full health, the most usual being linear regression using ordinary least squares (OLS). Although it is widely recognized that the EQ-5D questionnaire distribution violates the OLS regression assumptions of normality of the residual distribution and homoscedasticity, most studies that have compared alternative models concluded that the OLS gives the best overall performance in terms of indexes, such as R 2 and root mean square error (RMSE).
Methods that have been used to reflect the skewed distribution of the data or the upper bound include Tobit and median regression [2] , with the most common model being the censored least absolute deviation [4, 5] . Other approaches dealing with the common multimodal distribution of the data were two-part models (TPMs) and latent class models and in a more general form, mixture models [6, 10] . Pullenayegum et al. [11, 12] advise against Tobit and censored least absolute deviation models and recommend OLS with robust standard error estimation or TPM and latent class models if data are bimodal. Nonetheless, most published mapping studies have used cross-sectional designs and prediction models were derived from baseline data. Only a few studies have used repeatedly measured data; for example, Bansback et al. [8] used generalized estimating equations (GEEs) and Hernández Alava et al. [13] used an adjusted censored mixture model. This may be due to such data frequently being unavailable for the purpose of mapping; however, as such data become available, the need for appropriate analytical methods becomes increasingly important [14] . Other mapping approaches have attempted to map to the dimension level of the EQ-5D questionnaire and then apply the relevant tariff of utility values [15, 16] . In the absence of patient-level data, authors have also investigated mapping the mean non-preference-based scores to mean utility values, instead of subject-specific estimation [17] . The objective of the present article was to develop a reliable mapping algorithm to estimate EQ-5D questionnaire index values from the FACT-P instrument for use in cost-effectiveness analyses.
Methods

Study Sample and Instruments
Data from a multicenter, randomized, double-blind, placebocontrolled phase 3 trial in patients with metastatic castrationresistant prostate cancer (mCRPC) were used in this analysis. The study was conducted at 156 sites in 15 countries, and patients were enrolled from September 2009 through November 2010. Details on the study design and the inclusion/exclusion criteria are described elsewhere [18] .
HRQOL was measured by the preference-based EQ-5D questionnaire and the non-preference-based FACT-P instrument. Data on both instruments were collected at baseline visit and follow-up visits at week 13, 25, and every subsequent 12 weeks. The collection of EQ-5D questionnaire data was instituted at all sites in France, Germany, Italy, Spain, and the United Kingdom via an amendment to the protocol. Therefore, only those patients who were randomized after the Central Ethics Committee approval date qualified for the EQ-5D questionnaire data collection. Information on patients' demographic characteristics, treatment history, and extent of disease was collected at baseline. Moreover, a pain diary was collected 1 week before baseline and an assessment on the fatigue severity took place at baseline according to the National Cancer Institute Common Terminology Criteria for Adverse Events 4.0 criteria. Both arms of the trial were combined for the analysis presented here.
The FACT-P instrument (version 4) is a multidimensional, self-administered 39-item questionnaire composed of the FACTGeneral (FACT-G) original subscales, a general HRQOL instrument intended for patients with chronic illnesses, and a prostate cancer subscale (PCS) [19] . The FACT-G subscales are Physical Well-being (PWB), Social/Family Well-being (SWB), Emotional Well-being (EWB), and Functional Well-being (FWB). Each item is rated on a five-point Likert scale ranging from 0 (not at all) to 4 (very much) and a subscale as well as a total score calculated as the sum of the items comprising it after some items being reversed. The theoretical range of these scores is (0-156) for the FACT-P total score, (0-108) for the FACT-G total score, (0-28) for the PWB, SWB, and FWB, (0-24) for EWB, and (0-48) for PCS. A higher score indicates better quality of life.
The EQ-5D questionnaire has been designed as an international, standardized, generic instrument for describing and valuing HRQOL [20] . The EQ-5D questionnaire descriptive system includes five dimensions of health-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-with one question per domain. In the version used for this study, there are three levels of response, corresponding to increasing levels of impairment: no problems, some/moderate problems, and unable to/extreme problems. An EQ-5D questionnaire health state utility index is provided for each of the health states described by the instrument based on values provided in large general population studies. In this study, the UK preference weights have been applied [21] .
Methodology
Utility index values were treated as continuous variables. Three approaches were used to build prediction models described in detail in the following sections.
Generalized estimating equations
Because of the longitudinal nature of the study, observations from each instrument between visits are expected to be correlated. The GEE method was chosen as an adequate framework that allows for the longitudinal nature of the study to be taken into account and the covariance structure to be built. Two main types of models were considered: one with the FACT-P instrument total score as a covariate and the other one introducing the five domains scores of the FACT-P instrument. Patient and disease characteristics were also included in the prediction models: age, weight, Eastern Cooperative Oncology Group performance at baseline (0-1 or 2), previous chemotherapy regimens (1 or Z2), pain average score (o4 or Z4), and fatigue severity (0 or Z1). These were the main variables of interest and are typically collected in prostate cancer studies. Furthermore, it was expected that these variables would potentially have an effect on the EQ-5D questionnaire scores during the study. Variables were selected by using a backwards stepwise selection procedure removing variables that were not significant at the 0.05 level. We have not considered any interactions. A review of studies mapping (or cross walking) non-preference-based measures of health to generic preference-based measures revealed that moving from total or dimension to item-level models or adding interactions and other terms had quite modest and negligible improvements [22] . Increasing complexity in this way only rarely had a major effect on the range of scores being predicted and goodness of fit and was therefore not included in this analysis.
Two-part model
The EQ-5D questionnaire with UK weights takes values between À0.594 and 1. It is common to have a ceiling effect for higher values, that is, a high proportion of patients with value 1 indicating full health, which was also observed in our data (see left panel of Fig. 1 , histogram of observed EQ-5D questionnaire values). To reflect the ceiling effect in the data, we considered a TPM that consists of modeling the probability of attaining the upper bound (i.e., 1), and then model the remainder of the distribution below this bound. The probability of attaining a utility value of 1 was estimated by using a generalized logistic regression model, and the rest of the data, that is, utility less than 1, were accommodated by using a GEE model. The final predicted utility was calculated as a weighted sum of the probabilities of the two parts as follows: P(utility ¼ 1) Â 1 þ P(utility o1) Â predicted utility from the GEE model.
Group-specific model
We also evaluated the performance of fitting two different GEE models in two subsets of the data following the concerns of Kontodimopoulos et al. [14] . On the basis of the methodology presented in Versteegh et al. [23] to correct for the tendency of these models to overpredict in patients with poor health, we identified patients in poor health by FACT-P instrument scores
associated with the lower part of the EQ-5D questionnaire distribution. We considered that patients with a FACT-P instrument total score of lower than 76 indicated a poor health state. The cutoff selection was based on examining the percentage of patients with level "3" answers on the EQ-5D questionnaire domain scores.
For all three models, truncation was performed for predicted values exceeding the lower or upper value (À0.594 and 1, respectively). There was no particular pattern in the observed utility covariance matrix justifying a specific covariance structure such as the autoregressive one commonly encountered in longitudinal settings; thus, the exchangeable working covariance structure was assumed for the models. The GEE is a robust method regarding the covariance structure and provides consistent and asymptotically normal solutions for the model's coefficients even when the covariance structure is misspecified [24] .
Model Selection and Cross-Validation
The suitability of each fitted model was assessed by the RMSE and the mean absolute error (MAE), both quantifying the difference between the observed and predicted values. We examined both full and restricted models by excluding variables that were not significant at the 0.05 level. Furthermore, the variance explained by the model was assessed by the marginal R 2 [25] .
The percentage of truncated values over the number of predicted values was calculated for each model fitted.
The selected model was fitted to the full data set and crossvalidated by using a 10-fold in-sample cross-validation. Optimally, an external data set should be used to validate the model fit, but in the absence of this, an in-sample cross-validation is the secondbest choice. The study sample was randomly split into 10 equally sized groups. Each group was used as a validation data set, and the remaining 90% of the data were used to develop the model. The developed model was used on the validation data to predict the EQ-5D questionnaire values, which were then compared with the observed ones. The RMSE and the marginal R 2 were also calculated for all development and estimation samples. Their values were compared with the ones of the selected model fitted on the full data. Similarity between the 10 values was expected. Finally, the predicted values were also compared with the observed ones on the estimation sample by means of descriptive statistics. To determine whether the degree of error is evenly distributed across the scale of the EQ-5D questionnaire utility index, the mean and predicted means were also reported for subsets such as EQ-5D o 0, 0 r EQ-5D o 0.25, 0.25 r EQ-5D o 0.5, 0.5 r EQ-5D o 0.75, and 0.75 r EQ-5D r 1.
All models were fitted by using the SAS software version 9.2.
Results
Sample Characteristics
The number of patients with mCRPC in the estimation sample, that is, with both FACT-P instrument and EQ-5D questionnaire nonmissing scores simultaneously at one or more time points during the study, was 236 patients. Demographic and baseline characteristics for the estimation sample are presented in Table 1 , and baseline descriptive statistics for the FACT-P instrument and EQ-5D questionnaire scores are presented in Table 2 .
Mean FACT-P instrument domain and total scores in this sample are in line with similar studies on prostate cancer [2] . Full descriptive statistics for all scores and time points are shown in Table 1 
Model Selection
Models were compared on the basis of the smallest RMSE, MAE, and highest marginal R 2 . Results are shown in Table 3 for all models after truncation.
The group-specific model including the FACT-P subscale scores and baseline variables had the best predictive performance 
(R 2 ¼ 0.718, RMSE ¼ 0.162, and MAE ¼ 0.117). The PWB and PCS in the good health group and the PWB and EWB subscales in the poor health group had the highest explanatory value. The GEE on the total estimation sample and the TPM including the FACT-P instrument subdomain scores and baseline variables also had good predictive performance (see Table 3 ). Cross-validation gave similar index values for all 10 samples (results not shown).
Coefficients for the group-specific model are given in Table 4 , and a scatterplot of the observed compared with the predicted utility values is shown in Figure 1 (left panel). A Bland-Altman plot of the average observed and predicted utilities versus their difference is also provided in Figure 1 ( To assess whether the degree of error is evenly distributed across the full range of EQ-5D questionnaire values, we compared the mean error, MAE, and RMSE by subsets of the total range. Table 5 shows these indices for the overall distribution and for different subsets separately. Overall the mean utility index is accurately estimated as the low mean error indicates; nevertheless, there is overprediction for utility values under 0.5, which correspond to patients with "extreme problems" on at least one of the five EQ-5D questionnaire dimensions (poor health) and slight underprediction for the higher utility values (good health). This tendency is commonly observed in similar studies [16, 22, 23, 26] and is because the models fitted are aiming to model the mean utility rather than the whole distribution of non-normal utility values.
Discussion
In the absence of a preference-based outcome measure, a statistical model that maps the HRQOL measures commonly collected in prostate cancer clinical studies to utility values could prove useful. The estimation of these missing health-related utility data enables the calculation of quality-adjusted life-year and the analysis of costutility. Barton et al. [27] found that there were differences in qualityadjusted life-year gains when using observed or predicted by mapping utility values and encouraged the actual collection of preference-based measures, although they admit that their results may not be generalizable. NICE recommends the use of mapping techniques in the absence of directly collected preference-based outcome measures; however, the use of these techniques would lead to increased uncertainty around utility estimates and they should be considered a second-best solution [28] . We have estimated an algorithm to map to the EQ-5D questionnaire from the FACT-P instrument by using data from a sample of patients with prostate cancer. This analysis has demonstrated a method of incorporating data from repeated observations with good statistical properties.
Models published in the literature have mainly been based on linear regression using OLS. This is not adequate in prospective studies because it does not take into account the correlation between repeated measurements. Some authors have opted for using only the baseline data to estimate the OLS regression, and then use this to predict values at future time points [4, 14] . It has been discussed that a longitudinal study could provide evidence on the relationship of the changes of both instruments [9] . Given the fact that methods such as the GEE are now standard, we decided to use all available data under a longitudinal framework. EQ-5D, EuroQol five-dimensional; FACT-P, Functional Assessment of Cancer Therapy-Prostate; WB, well-being.
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Health-related utility data are bounded at a value of 1 representing full health, and data obtained from the EQ-5D questionnaire usually exhibit a ceiling effect (e.g., percentage of perfect health in the estimation sample was 22% across all visits). We accommodated this by fitting a TPM, the first part of which is modeling the probability of presenting full health and the second a standard GEE to predict values of less than 1. A floor effect was not a concern in our data set (percentage of worst utility value was 0.5% across all visits). This reduced the amount of truncation needed. Furthermore, we investigated the adequacy of fitting two separate GEE models for patients with poor and good health to deal with over-and underprediction observed in other studies and in the first two techniques. Mapping to the individual EQ-5D questionnaire domains could provide additional information at an item level, but was not considered for this data set because there were very few observations with the most severe level for each domain to provide an adequate fit to a multinomial logistic regression model (percentages of the most severe level for each domain were 1.23% for mobility, 1.54% for self-care, 6.31% for usual activities, 6.63% for pain/discomfort, and 3.85% for anxiety/ depression).
The models developed in this article had a good predictive ability, with RMSE between 0.162 and 0.170, MAE between 0.117 and 0.124, and a marginal R 2 between 0.691 and 0.718. Brazier et al. [22] in their systematic review of mapping studies reported one of the best models in terms of performance as one with an R 2 of 0.51 and a range of 0.17 to 0.71. The authors also reported a range for RMSE from 0.084 to 0.2 and for MAE from 0.0011 to 0.19 in the studies included in the review. This review also identified a similar study that mapped the FACT-P instrument scores to EQ-5D questionnaire utility values in a prostate cancer population [2] .
Only baseline values were used to develop the algorithm for this study, and OLS and median regression models were used. The selected model in this study explained 58.2% of the variability in EQ-5D questionnaire observed values and had an MAE of 0.146. As in other oncology studies in which the FACT-G instrument or the Full model using individual components of the FACT-P instrument; and Model 4: Restricted model using individual components of the FACT-P instrument. cancer-specific Functional Assessment of Chronic Illness Therapy instrument is mapped to the EQ-5D questionnaire, we found that the Social/Family Well-being domain did not significantly affect the EQ-5D questionnaire score. The methods used were not free of limitations. The GEE models the mean of the response variable, which obliges the means of the observed and predicted values to be similar and could possibly conceal a misfit in the lower or upper end of the data distribution. This is especially true when dealing with highly skewed data with a ceiling effect, such as the EQ-5D questionnaire data, whose distribution is far from normal. The general fit though is rather satisfactory with R 2 higher than in previous studies found in the literature and RMSE and MAE within the range seen in previous studies [22] . One way to avoid this is to predict a mean cohort EQ-5D questionnaire utility index directly by using the mean score of the disease-specific instrument instead of the individual subject predictions, as in Ara and Brazier [17] .
The group-specific model was fitted to decrease the prediction error in the lower and upper end of the distribution compared with the GEE model (total cohort) and the TPMs. The results presented by the EQ-5D questionnaire range showed that although providing a reduction in the MAE for the lower range, there was no improvement in the RMSE. This is due to a small number of predictions at the very end of the scale with high errors (see Fig. 1, left panel) . In applying the algorithm, it is important to consider the likely proportion of patients at the severe end of the scale where the error in the prediction is greater. The proportion of patients with utility values lower than 0.5 was modest (12.9% in the estimation sample). We have not been able to identify studies on mCRPC in which the EQ-5D questionnaire values were reported by the range, but because our baseline mean EQ-5D questionnaire value of 0.688 is within the range of average utility values reported in other studies [2, [29] [30] [31] , we do not expect the sample to be atypical of patients with mCRPC.
Mapping algorithms have proven to be useful alternatives in the absence of EQ-5D questionnaire data collection in studies in which economic evaluations are to follow. Our results confirm that utility values can be predicted when data on an HRQOL nonpreference-based instrument are collected.
Source 
Supplemental Materials
Supplemental materials accompanying this article can be found in the online version as a hyperlink at http://dx.doi.org/10.1016/j. jval.2013.12.005 or, if a hard copy of article, at www.valueinhealth journal.com/issues (select volume, issue, and article).
